Gain detailed insights into the trading activity of Congress members for Sabra Health Care REIT on our government trades page. Stay updated on how elected officials are investing in SBRA.

Sabra Health Care REIT - Government Trades

Sabra Health Care REIT

Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.

Long Ideas

News

Markets

Media

Trading Ideas

ASML

SBRA

STLD

On CNBC’s &#34;Halftime Report Final Trades,&#34; Jim Lebenthal of Cerity Partners said if you are looking for a stock that’s on the verge of 

Deere, ASML, Steel Dynamics And A Real Estate Stock: CNBC&#39;s &#39;Final Trades&#39;

Modern,Hospital,Style,Building

REIT

Real Estate

CTRE

Healthcare REITs Showing Strong Performance In February

$LTC

PEAK

WELL

Analyst Initiates Coverage On 10 Healthcare REITs, But Which Ones Are Buys?

On CNBC’s &#34;Halftime Report Final Trades,&#34;  Jenny Harrington of Gilman Hill Asset Management said  Sabra Health Care REIT, Inc. (NASDAQ: SBRA) has a 9% yield and 

Nucor, Sabra Health Care And A Major Investment Bank: CNBC&#39;s &#39;Final Trades&#39;

EMXC

INVH

On CNBC’s &#34;Halftime Report Final Trades,&#34;  Josh Brown  of Ritholtz Wealth Management said he is staying long

Invitation Homes, Tradeweb Markets, Sabra Health Care And More On CNBC&#39;s &#39;Final Trades&#39;

Miniature,Wooden,Houses,And,A,Red,Arrow,Down.,The,Concept

3 REITs That Were Hit With Downgrades This Week

Analysts Just Upgraded These Three Healthcare REITs

Concept,Of,Several,Properties,In,A,City,Generating,Passive,Income

GIPR

LAMR

SBAC

The 3 Best-Performing REITs In September

Short Ideas

Small Cap

Pre-Market Outlook

The most overbought stocks in the real estate sector presents an opportunity to go short on these overvalued companies.

Top 2 Real Estate Stocks That Are Ticking Portfolio Bombs

Analysts: Healthcare REITs Show A Dichotomy Of Performance

Sabra Health Care REIT, Inc. - Common Stock

Sabra Health Care REIT Inc

Truist Securities analyst Michael Lewis maintains Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) with a Buy and raises the price target from $15 to $16.

Price Target

Analyst Ratings

Truist Securities Maintains Buy on Sabra Health Care REIT, Raises Price Target to $16

A significant insider buy by Catherine Cusack, Director at Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>), was executed on May 23, and reported in the recent SEC filing.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001492298/000186212824000026//Archives/edgar/data/1492298/000186212824000026/0001862128-24-000026-index.htm">U.S. Securities and Exchange Commission</a> on Thursday unveiled that Cusack made a notable purchase of 7,000 shares of Sabra Health Care REIT, valuing at $101,010.
The latest update on Friday morning shows Sabra Health Care REIT shares up by 1.73%, trading at $14.39.
<h3>Unveiling the Story Behind Sabra Health Care REIT</h3>
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
<h3>Unraveling the Financial Story of Sabra Health Care REIT</h3>
Positive Revenue Trend: Examining Sabra Health Care REIT's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 3.36% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Real Estate sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 67.62%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Sabra Health Care REIT's EPS reflects a decline, falling below the industry average with a current EPS of 0.11.
</li>
</ul>
Debt Management: Sabra Health Care REIT's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.9.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: Sabra Health Care REIT's current Price to Earnings (P/E) ratio of 67.38 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 5.06 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Boasting an EV/EBITDA ratio of 16.93, Sabra Health Care REIT demonstrates a robust market valuation, outperforming industry benchmarks.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
Considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Unlocking the Meaning of Transaction Codes</h3>
Digging into the details of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001492298">Check Out The Full List Of Sabra Health Care REIT's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Eye On Growth: Catherine Cusack Adds $101K Of Sabra Health Care REIT Stock To Portfolio

Scotiabank analyst Nicholas Yulico maintains Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) with a Sector Perform and raises the price target from $14 to $15.

Scotiabank Maintains Sector Perform on Sabra Health Care REIT, Raises Price Target to $15

2024 GUIDANCE
Sabra is reiterating 2024 earnings guidance ranges as follows (attributable to common stockholders, per diluted common share):
<ul>
<li>Net Income: $0.53 - $0.57</li>
<li>FFO: $1.33 - $1.37</li>
<li>Normalized FFO: $1.34 - $1.38</li>
<li>AFFO: $1.38 - $1.42</li>
<li>Normalized AFFO: $1.39 - $1.43</li>
</ul>
Earnings guidance above assumes no 2024 acquisition or disposition activity.
Commenting on the first quarter's results, Rick Matros, CEO and Chair, said, "As has been evident for several quarters, Sabra's portfolio continues to grow stronger, whether looking at coverage, occupancy, or NOI. Trailing-twelve-month SNF coverage saw a healthy 0.06x increase sequentially, to 1.79x, when excluding the impact of Provider Relief Funds. Our SHOP portfolio continues to improve, and this quarter's results - which faced a challenging year-over-year comp - are in line with our expectations embedded in guidance. Our balance sheet remains strong and is poised to support future growth.
Although we have no new investments to discuss this quarter, the pipeline has improved and with what we are working on, we expect to announce new investments on our second quarter call."

Guidance

Sabra Health Care REIT Sees FY24 Normalized AFFO $1.39-$1.43

Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.33 by 6.06 percent. This is a 2.94 percent increase over earnings of $0.34 per share from the same period last year. The company reported quarterly sales of $166.75 million which beat the analyst consensus estimate of $159.88 million by 4.30 percent. This is a 3.36 percent increase over sales of $161.32 million the same period last year.

Earnings

Earnings Beats

Sabra Health Care REIT Q1 FFO $0.35 Beats $0.33 Estimate, Sales $166.75M Beat $159.88M Estimate

On CNBC&rsquo;s &quot;<a href="https://www.cnbc.com/video/2024/03/25/final-trades-steel-dynamics-sabra-health-care-asml-holding-and-deere.html">Halftime Report Final Trades</a>,&quot; Jim Lebenthal of Cerity Partners said if you are looking for a stock that&rsquo;s on the verge of <a href="https://www.benzinga.com/news/earnings/24/02/37159985/why-heavy-equipment-maker-deere-shares-are-taking-a-hit-today"> breaking out, Deere &amp; Company (NYSE: </a><a class="ticker" href="https://www.benzinga.com/stock/de#NYSE">DE</a>).
On March 25, Deere &amp; Company said former Eastman Chemical Company executive, Kellye Walker, will join its leadership team as senior vice president, chief legal officer and worldwide public affairs, effective April 29.
Stephen Weiss of Short Hills Capital Partners picked ASML Holding N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asml#NASDAQ">ASML</a>), saying that it&rsquo;s a great story.
On March 25, ASML reported transactions under its current share buyback program.
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a> 
Jenny Van Leeuwen Harrington of Gilman Hill Asset Management, LLC named Sabra Health Care REIT, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sbra#NASDAQ">SBRA</a>), which has an 8.4% dividend yield.
On Feb. 27, Sabra Health Care REIT posted better-than-expected sales results for its fourth quarter.
Joseph M. Terranova of Virtus Investment Partners said Steel Dynamics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stld#NASDAQ">STLD</a>) is breaking out.
On March 15, Steel Dynamics provided first-quarter 2024 earnings guidance. The company said it expects EPS of $3.51 to $3.55 vs. street view of $3.35, expecting profitability from the steel operations to be meaningfully stronger Q/Q on higher shipments and earnings across the platform.
<h3>Price Action</h3>
<ul>
<li>Deere shares fell 0.2% to settle at $398.03 on Monday.</li>
<li>ASML shares fell 0.1% to close at $978.93 on Monday.</li>
<li>Sabra Health Care gained 1.2% to settle at $14.45 during Monday&rsquo;s session.</li>
<li>Steel Dynamics shares gained 0.1% to close at $144.15 on Monday.</li>
</ul>
Image: Shutterstock 
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/03/37908147/how-to-earn-500-a-month-from-td-synnex-stock-ahead-of-q1-earnings-report"> How To Earn $500 A Month From TD Synnex Stock Ahead Of Q1 Earnings Report </a>

Deere, ASML, Steel Dynamics And A Real Estate Stock: CNBC's 'Final Trades'

CNBC Halftime Report Final Trades: Steel Dynamics, Sabra Health Care REIT, ASML Holding, Deere & Company

Sabra Health Care REIT Sees FY24 Normalized AFFO $1.39-$1.43 Vs $1.38 Est.

Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) reported quarterly earnings of $0.33 per share which met the analyst consensus estimate. The company reported quarterly sales of $163.40 million which beat the analyst consensus estimate of $158.10 million by 3.35 percent. This is a 0.96 percent decrease over sales of $164.99 million the same period last year.

Sabra Health Care REIT Q4 2023 GAAP EPS $0.33, Inline, Sales $163.40M Beat $158.10M Estimate

Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) reported quarterly sales of $163.40 million which beat the analyst consensus estimate of $158.10 million by 3.35 percent. This is a 0.96 percent decrease over sales of $164.99 million the same period last year.

Sabra Health Care REIT Q4 Sales $163.40M Beat $158.10M Estimate

ACAD

ACHC

AESI

AHCO

AIRS

ALEC

ALHC

AMBA

AMBC

APLS

ARKO

ARQT

ARRY

ATEC

AXON

BCSF

BECN

BGFV

BMBL

BWXT

BYND

CAVA

CBRL

CIVI

CLDT

CLNE

CLVT

CMLS

COMP

CPNG

CRDO

CYTK

EBAY

EHTH

ESPR

FARO

FLYW

FOUR

FSLR

FULC

GDOT

GLPI

GMRE

GSX Techedu Inc. American Depositary Shares

GOTU

GPOR

HRZN

HSIC

HURN

ICCC

ICFI

ICUI

IMAX

IMXI

INGN

INSE

IPAR

JAMF

KIND

KURA

KVYO

LAZR

LGND

LGVN

Earnings Scheduled For February 27, 2024

Investors looking to own winning stocks need to know which sectors are outperforming other sectors when making purchase decisions. With real estate investment trusts (REITs), subsectors go in and out of favor based on economic news, earnings and technical indicators such as being overbought or oversold.
A few months ago, office REITs were trouncing other subsectors. However, over the last week, healthcare REITs have emerged as the new leader among REITs. The healthcare REIT sub sector was not a great overall performer in 2023, but things may be turning around in 2024.
Take a look at four healthcare REITs that have shown strong performance since the close of trading on Feb. 5.
Medical Properties Trust Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPW#NYSE">MPW</a>) is a Birmingham, Alabama-based healthcare REIT that owns and operates 441 general acute care and other properties across the U.S. and in nine other countries, including locations in Europe and Australia. It has a portfolio valued at $19 billion, of which about 64% are general acute care hospitals. About two-thirds of its properties are in the United States.&nbsp;
Medical Properties Trust was one of the worst performing of all REITs in January, following its update on its largest tenant, Steward Health Care System. The share price fell more than 30% after Medical Properties said it's accelerating its efforts to recover uncollected rents from the fourth quarter of 2023 and outstanding loan obligations from Steward. Medical Properties also agreed to fund a new $60 million bridge loan to Steward, secured by preexisting collateral plus a new second lien on Steward's managed care business.
In addition, Steward said it would explore the possible sale or re-tenanting of certain hospital operations along with the divestiture of non-core operations. At the end of 2023, Steward still owed approximately $50 million to Medical Properties Trust.
Lately, Medical Properties Trust has been a hot stock, up 10.73% since Feb. 5. There has been no news or analyst upgrades, and its fourth-quarter earnings don't come out until Feb. 21, so perhaps it's just an oversold bounce.
Omega Healthcare Investors Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) is a Hunt Valley, Maryland-based triple-net equity healthcare REIT that provides financing, capital and leasing to 69 operators of 862 senior housing, skilled nursing and assisted living facilities across 42 states throughout the U.S. and the United Kingdom. Omega Healthcare Investors has no part in the day-to-day management of these facilities, which are run by the operators.
On Jan. 30, Deutsch bank analyst Omotayo Okusanya initiated coverage on Omega Healthcare Investors with a Buy rating and announced a price target of $36.
On Feb. 7, Omega Healthcare reported its fourth-quarter operating results. Funds from operations (FFO) of $0.68 per share beat the analysts' estimate of $0.67 per share but was below FFO of $0.73 in the fourth quarter of 2022. Revenue of $239.32 million beat the estimates of $233.82 million and the fourth-quarter 2022 revenue of $144.85 million by 65.22%.
On the strength of its earnings report, Omega Healthcare is up 10.3% since Feb. 5.
Caretrust REIT Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRE#NYSE">CTRE</a>) is a San Clemente, California-based healthcare REIT, founded in 2013, that owns and leases senior housing, skilled nursing facilities (SNF) and assisted living facilities (ALF). As of Dec. 31, its long-term net-lease portfolio consisted of 207 properties across 25 states with 23 property operators. Skilled nursing facilities account for 71.5% of its portfolio, 8.8% is senior housing and the remaining 19.7% is multiservice campus.
On Jan. 31, RBC Capital Markets analyst Michael Carroll maintained an Outperform rating on Caretrust and lowered the price target from $25 to $24.
On Feb. 8, Caretrust reported fourth-quarter operating results. FFO of $0.36 was in line with estimates but a decrease from FFO of $0.38 in the same quarter a year ago. But revenue of $59.73 million was 11.61% above analyst estimates of $53.52 million and a 15.29% increase over revenue of $51.81 million in the fourth quarter of 2022.
Since Feb. 5, Caretrust has risen 10.32%. Investors were impressed with the fourth-quarter results.
Sabra Health Care REIT Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) is an Irvine, California-based healthcare REIT that as of Sept. 30 has 410 investments across the U.S. Its portfolio consists of senior nursing facilities (SNF), senior housing, behavioral health and specialty hospitals with eight-year weighted average lease terms (WALT). Signature Healthcare is its largest tenant, with a rent concentration of 9%.
Sabra CEO Rick Matros recently told analysts that occupancy gains and easing labor pressures are driving rent coverage higher and Medicaid reimbursements have also been increasing. Sabra sold 13 SNFs and two senior housing facilities during the third quarter with net proceeds used to reduce the outstanding balance on Sabra's revolving credit facility.
On Jan. 30, Deutsch bank analyst Omotayo Okusanya initiated coverage on Sabra Health Care with a Buy rating and announced a price target of $21. The following day, Jenny Harrington of Gilman Hill Asset Management also recommended it on CNBC.
Sabra Health Care has climbed 7% since Feb. 5.
Explore Opportunities Beyond REITs
While publicly traded REITs offer a convenient way to invest in real estate, we believe that some of the most compelling opportunities lie in the private market. Benzinga's <a href="https://www.benzinga.com/alternative-investments/real-estate">real estate offering screener</a> features a curated selection of private market real estate offerings from trusted platforms with a track record of strong returns.
Whether you&#8217;re an accredited or non-accredited investor, you can filter opportunities based on your investment criteria, including minimum investment, property type and target return. These offerings provide a unique chance to diversify your portfolio and tap into potential high-yield investments that are not available on public exchanges.
<a href="https://www.benzinga.com/alternative-investments/real-estate">Browse offerings</a>
Latest Private Market Offerings
<ul>
<li><a href="https://www.benzinga.com/alternative-investments/listing/horizon-village">Horizon Village</a>: Grocery-anchored shopping center located in Phoenix, AZ, with a target return of 12%.</li>
<li><a href="https://www.benzinga.com/alternative-investments/listing/coop-at-eado">COOP @ EaDo</a>: Class A multifamily development with a 99-year property tax exemption and a target return of 20.9%</li>
<li><a href="https://www.benzinga.com/alternative-investments/listing/multi-family-portfolio-fund">Multi-Family Portfolio Fund</a>: Portfolio of existing class &#8216;B &amp; C&#8217; multi-family assets in the West &amp; South Western United States and a minimum investment of only $500.</li>
</ul>
Discover these and other exclusive real estate investment opportunities on Benzinga's offering screener. Dive into the private market and uncover the potential for substantial returns beyond the public REIT market.

Friday marks the last chance for investors to receive the next dividend payout from Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>). 
<h3>What's Happening</h3>
The company announced on Thursday that it would pay shareholders a quarterly dividend of 30 cents per share. On Monday, Sabra Health Care REIT will go ex-dividend, meaning the stock will trade lower to reflect that payout. In other words, the stock will likely open 30 cents lower than it would have opened on any other day.
In order to be eligible to receive a company's dividend, shareholders must own the stock prior to the ex-dividend date—in this case, Monday. Shareholders who own SBRA as of the end of Friday's session are eligible to receive the 30 cents dividend payout for every share that they own. 
According to the company, this dividend will be paid out to shareholders on February 29, 2024. Investors will then be able to either reinvest those dividends back into the stock or use the payment in some other way. 
To keep track of which companies are distributing dividends, <a href="https://www.benzinga.com/calendars/dividends">click here</a> to visit our Dividends Calendar.

Dividends

Friday Is Your Last Chance To Buy Sabra Health Care REIT Before The Dividend Payout

When analysts initiate coverage on a stock, it means the analyst will begin to provide research on a stock and make investment recommendations on it for the first time. This move is important because it typically leads to an increase in trading volume and interest among investors. It can ultimately help shares of those stocks to move higher, depending upon the rating given.
Usually, the analyst will start with two or three similar stocks at one time. But every once in a while, an analyst will begin coverage on a larger group within a subsector.
This week, on January 30, 2024, was one of those instances, as ten healthcare real estate investment trusts (REITs) had coverage initiated by a single analyst, but only six of the ten were rated "Buys."&nbsp;
Sabra Health Care REIT Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) is an Irvine, California-based healthcare REIT that owns 410 properties across the U.S. Its portfolio consists of Senior Nursing Facilities (SNF), Senior Housing, Behavioral Health and Specialty Hospitals with eight-year weighted average lease terms (WALT). Signature Healthcare is its largest tenant, with a rent concentration of 9%.
Sabra CEO Rick Matros recently told analysts that occupancy gains and easing labor pressures are driving rent coverage higher and Medicaid reimbursements are likely to increase. Thirteen SNF and two Senior Housing facilities were sold during Q3 2023 with the net proceeds used to reduce the outstanding balance on Sabra's revolving credit facility.
On January 30, Deutsch bank analyst Omotayo Okusanya initiated coverage on Sabra Health Care with a Buy rating and announced a price target of $21. Earlier in the month, Mizuho analyst Vikram Malhotra also maintained a Buy rating on Sabra Health, while raising the target price from $15 to $17.
Sabra Health Care has a total return of -5.00% in 2024.
<h2 class="wp-block-heading">Don't Miss:</h2>
<ul>
<li>Investing in real estate just got a whole lot simpler. This<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> Jeff Bezos-backed startup</a> will allow you to become a landlord in just 10 minutes, and you only need $100.</li>
<li>Passive income investments are one of the most trusted methods for riding out a recession, so it's no surprise that people are turning to these <a href="https://www.benzinga.com/money/godwin-capital-notes">high-yield commercial real estate notes that pay a fixed 10% &#8211; 12%.</a></li>
</ul>
Welltower Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) is a Toledo, Ohio, based healthcare REIT that owns interests in housing for seniors, post-acute communities and outpatient medical properties. It does this by providing capital to the operators who run these facilities. Welltower was founded in 1970 under the original name of Health Care Fund and was incorporated as a REIT in 1985. Welltower is a member of the S&amp;P 500.
Welltower has a total portfolio of 2017 properties, consisting of Senior Housing, Outpatient Medical and Long-Term/Post-Acute care across the U.S. The average age of the facilities is 20 years.
Deutsch bank analyst Omotayo Okusanya initiated coverage on Welltower with a Buy rating and announced a $115 price target. Earlier in the month Keybanc analyst Todd Thomas had maintained an overweight rating while raising the price target from $90 to $95.
Welltower was one of the 15 best-performing REITs of 2023, with a total return of 39.64%, but thus far in 2024 the total return is -3.40%.
Ventas Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) is a Chicago-based diversified healthcare REIT with approximately 1,400 properties that include senior living communities, life science, research and innovation properties, medical office buildings, outpatient facilities and skilled nursing facilities. Ventas has been in business for over 20 years and is a member of the S&amp;P 500.
Deutsch bank analyst Omotayo Okusanya initiated coverage on Ventas with a Buy rating and announced a price target of $60. On January 16, 2023, Bank of America Securities analyst Joshua Dennerlein upgraded Ventas from Neutral to Buy and raised the price target from $48 to $53.
Ventas has a total return of -4.90% in 2024.
National Health Investors Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) is a Murfreesboro, Tennessee-based healthcare REIT that specializes in sale-leaseback, joint-venture, mortgage and mezzanine financing of senior housing and medical investments. Its portfolio of 192 properties consists of independent living, assisted living, memory care communities, skilled nursing facilities, medical office buildings and specialty hospitals. National Health Investors was incorporated in 1991.
Deutsch bank analyst Omotayo Okusanya initiated coverage on National Health Investors with a Buy rating and announced a price target of $6.
National Health Investors has a total return in 2024 of -2.66%.
Omega Healthcare Investors Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) is a Hunt Valley, MD triple-net equity healthcare REIT that provides financing, capital and leasing to 66 different operators in 883 senior housing, skilled nursing and assisted living facilities across 42 states throughout the U.S. and the United Kingdom. Omega Healthcare Investors has no part in the day-to-day management of these facilities, which are run by the operators.
Deutsch bank analyst Omotayo Okusanya initiated coverage on Omega Healthcare Investors with a Buy rating and announced a price target of $36.
Omega Healthcare has a total return of -5.02% in 2024.
Three other healthcare REITs, Healthcare Realty Trust Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>), LTC Properties Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTC#NYSE">LTC</a>) and Healthpeak Properties Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEAK#NYSE">PEAK</a>) also had coverage initiated on January 30 and received Hold Ratings. Price targets for the three were $18, $34 and $21 respectively.
Medical Properties Trust Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPW#NYSE">MPW</a>), which is already down 36% in 2024, was tagged with a Sell rating and a price target of $2.
Healthcare REITs have shown improvements in occupancy and ability to restructure leases with operators, but not all healthcare REITs have been equal in making these changes, and that is reflected in the various ratings by Okusanya.
Investors should keep in mind that analysts are only correct about 50% of the time, and it's best for investors to perform their own due diligence before making purchase or sell transactions.
<h2 class="wp-block-heading">Read Next:</h2>
<ul>
<li>Elon Musk has reportedly bought 6,000 acres of land just outside of Austin.<a href="https://www.benzinga.com/real-estate/23/05/32537165/elon-musk-is-bullish-on-austin-heres-how-to-invest-in-the-citys-growth-before-he-floods-it-with-new"> Here&#8217;s how to invest in the city&#8217;s growth</a> before he floods it with new tech workers.</li>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/3-high-yield-investments-boost-income">Here are 3 high-yield investments to add significant income to your portfolio</a>.</li>
<li>Collecting passive income from real estate just got a whole lot simpler. A new<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> real estate fund backed by Jeff Bezos</a> gives you instant access to a diversified portfolio of rental properties, and you only need $100 to get started.</li>
</ul>

On CNBC&rsquo;s &quot;<a href="https://www.cnbc.com/video/2024/01/30/final-trades-nucor-sabra-healthcare-and-goldman-sachs.html">Halftime Report Final Trades</a>,&quot; Jenny Harrington of Gilman Hill Asset Management said Sabra Health Care REIT, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sbra#NASDAQ">SBRA</a>) has a 9% yield and <a href="https://www.benzinga.com/quote/SBRA/news"> 5% earnings growth. </a>
Deutsche Bank analyst Omotayo Okusanya initiated coverage on Sabra Health Care REIT with a Buy rating and announced a price target of $21. Sabra Health Care recently named Jessica Flores as executive vice president and chief accounting officer.
Josh Brown of Ritholtz Wealth Management picked&nbsp;The Goldman Sachs Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gs#NYSE">GS</a>). It looks like a breakout is in progress, he added.
On Tuesday, Morgan Stanley analyst Betsy Graseck upgraded Goldman Sachs from Equal-Weight to Overweight and raised the price target from $333 to $449. Oppenheimer analyst Chris Kotowski maintained the stock with an Outperform and raised the price target from $491 to $506.
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a> 
Joe Terranova of Virtus Investment Partners named Nucor Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nue#NYSE">NUE</a>), which reported upbeat quarterly earnings on Monday.
Nucor reported fourth-quarter earnings of $3.16 per share, which topped analyst estimates of $2.87 per share. Quarterly sales of $7.70 billion clocked in above analyst expectations of $7.65 billion, an 11.74% decrease over sales of $8.72 billion <a href="https://www.benzinga.com/news/earnings/24/01/36835663/nucor-posts-q4-earnings-beat-states-it-sees-an-increase-in-q1-earnings-stock-rises">from the same period last year.</a>
Price Action:
<ul>
<li>Sabra Health Care shares gained 0.7% to close at $13.58 on Tuesday.</li>
<li>Shares of Goldman Sachs rose 1.7% to close at $386.87 on Tuesday.</li>
<li>Nucor shares gained 6.9% to settle at $188.90 during Tuesday&rsquo;s session.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/01/36777889/insiders-buying-compass-minerals-international-and-2-other-stocks"> Insiders Buying Compass Minerals International And 2 Other Stocks</a>
Photo: Shutterstock

Nucor, Sabra Health Care And A Major Investment Bank: CNBC's 'Final Trades'

Deutsche Bank analyst Omotayo Okusanya initiates coverage on Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) with a Buy rating and announces Price Target of $21.

Initiation

Deutsche Bank Initiates Coverage On Sabra Health Care REIT with Buy Rating, Announces Price Target of $21

In the preceding three months, 5 analysts have released ratings for Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $15.8, a high estimate of $17.00, and a low estimate of $15.00. This current average reflects an increase of 12.86% from the previous average price target of $14.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1704304823_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of Sabra Health Care REIT's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vikram Malhotra</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$17.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Stephen Manaker</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Connor Siversky</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>John Kim</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$16.00</td>
<td>-</td>
</tr>
<tr>
<td>Connor Siversky</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Sabra Health Care REIT. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Sabra Health Care REIT compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Sabra Health Care REIT's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Sabra Health Care REIT's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SBRA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sabra Health Care REIT analyst ratings.</a>
<h2>Delving into Sabra Health Care REIT's Background</h2>
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities. The company considers merger and acquisition investment as a component of its operational growth strategy. Sabra works with existing operators to identify strategic development opportunities.
<h3>Sabra Health Care REIT's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Sabra Health Care REIT showcased positive performance, achieving a revenue growth rate of 14.82% as of 30 September, 2023. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -9.34%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Sabra Health Care REIT's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -0.52%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Sabra Health Care REIT's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.28%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.82, Sabra Health Care REIT adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Sabra Health Care REIT

Mizuho analyst Vikram Malhotra maintains Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) with a Buy and raises the price target from $15 to $17.

Mizuho Maintains Buy on Sabra Health Care REIT, Raises Price Target to $17

On CNBC&rsquo;s &quot;<a href="https://www.cnbc.com/video/2023/11/20/final-trades-tradeweb-emerging-markets-more.html">Halftime Report Final Trades</a>,&quot; Josh&nbsp;Brown of Ritholtz Wealth Management said he <a href="http://www.benzinga.com/analyst-ratings/analyst-color/23/10/35494354/invitation-homes-is-an-attractive-2024-story-says-this-bullish-analyst">is staying long on</a> Invitation Homes Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/invh#NYSE">INVH</a>).
Invitation Homes reported better-than-expected sales results for its third quarter and revised its FY23 core FFO per share guidance.
Jenny Harrington of Gilman Hill Asset Management said Sabra Health Care REIT, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sbra#NASDAQ">SBRA</a>) has an 8.5% dividend yield.
Sabra Health Care recently posted stronger-than-expected sales for its third quarter.
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a> 
Liz Young of BNY Mellon Investment Management named iShares MSCI Emerging Markets ex China ETF (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/emxc#NASDAQ">EMXC</a>) as her final trade.
Joseph Terranova of Virtus Investment Partners picked Tradeweb Markets Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tw#NASDAQ">TW</a>).
Tradeweb Markets inked a definitive agreement to acquire r8fin for an undisclosed amount.
Price Action:&nbsp;Invitation Homes shares fell 0.1% to close at $33.50, while Sabra Health Care shares rose 1.9% to settle at $14.57 on Monday. Tradeweb Markets closed at $93.42, while iShares MSCI Emerging Markets ex China ETF rose 0.9% during Monday&rsquo;s session.
Check This Out: <a href="https://www.benzinga.com/news/earnings/23/11/35887407/nvidia-best-buy-and-3-stocks-to-watch-heading-into-tuesday"> NVIDIA, Best Buy And 3 Stocks To Watch Heading Into Tuesday</a>
Photo: Shutterstock

Invitation Homes, Tradeweb Markets, Sabra Health Care And More On CNBC's 'Final Trades'

CNBC Halftime Report Final Trades: Invitation Homes, Sabra Health Care REIT

SBRA, GH and CRBU are among after hour movers

Rally Gets Reality Check

Picking A Winner In Healthcare REITs

As I have previously discussed, I recently attended REITweek, the largest real estate investment trust event of the year. And I have to say, I'm cautiously optimistic about commercial real estate. Here is a look at some key themes from the event.

Three Key Themes From REITweek

In a report released on June 13, Vikram Malhotra from Mizuho Securities maintained a Buy rating on Sabra Healthcare REIT (SBRA – Research Report), ...

Sabra Healthcare REIT (SBRA) Receives a Buy from Mizuho Securities

CareTrust REIT: A Growing REIT That Deserves A Spot In Your Portfolio

The healthcare REIT industry is poised for robust growth thanks to the diversification of portfolios, rising healthcare expenditure, and an uptick in chronic diseases, making it ideal for investors looking for exposure to the healthcare sector. Therefore, investors could look to add high-growth healthcare REIT stocks Welltower (WELL), CareTrust REIT (CTRE), and Sabra Health Care REIT (SBRA) to their watchlists. Read on… The growth prospects for healthcare Real Estate Investment Trusts (REITs) are promising. They are driven by demographic trends, increasing healthcare spending, technological advancements, and consolidation in the healthcare industry.
Amid this backdrop, investors could consider adding high-growth healthcare REIT stocks, Welltower Inc. (<a href="https://stocknews.com/stock/WELL/">WELL</a>), CareTrust REIT, Inc. (<a href="https://stocknews.com/stock/CTRE/">CTRE</a>), and Sabra Health Care REIT, Inc. (<a href="https://stocknews.com/stock/SBRA/">SBRA</a>) to their watchlists. Before exploring the fundamentals of these stocks, let's first understand what's shaping the healthcare REIT industry's prospects.
Healthcare REITs typically own a diversified portfolio of healthcare properties, including hospitals, medical office buildings, senior housing, and skilled nursing facilities. This diversification helps mitigate risk and provides opportunities for growth across different sectors of the healthcare industry.
The aging population in the United States is driving demand for healthcare services, creating opportunities for healthcare REITs to capitalize on the growing market. Healthcare spending is increasing due to factors such as technological advancements, rising chronic disease rates, and the expansion of healthcare coverage, leading to a need for more healthcare facilities.
In the first quarter of 2024, healthcare REITs showed strong leasing performance and favorable lease terms in medical office sectors, reporting an <a href="https://www.reit.com/what-reit/reit-sectors/health-care">FFO of $667 million</a>. Market conditions for healthcare REITs show cap rates tightening for quality medical office properties due to high investor demand and stable income profiles.
Healthcare real estate has a history of strong fundamentals, with stable tenant leases and consistent rental income. Healthcare REITs benefit from high occupancy rates and long-term leases, providing a stable income stream and potential for growth. Furthermore, the REIT market is poised to reach $333.01 billion by 2027, growing at a <a href="https://www.technavio.com/report/reit-market-analysis">CAGR of 2.8%</a>.
With these favorable trends in mind, let's delve into the fundamentals of the three <a href="https://stocknews.com/category/reits-healthcare/">REITs - Healthcare</a> stocks, starting with the third in line.
Stock #3: Welltower Inc. (<a href="https://stocknews.com/stock/WELL/">WELL</a>)
WELL drives the transformation of healthcare infrastructure. It invests with leading senior housing operators, post-acute providers, and health systems to fund the real estate and infrastructure needed to scale innovative care delivery models and improve people's wellness and overall healthcare experience. 
WELL has been paying dividends to its shareholders for the past 34 years. Its annualized dividend of $2.44 per share translates to a dividend yield of 2.36% on the current share price. Its four-year average yield is 3.36%.
Over the past three and five years, WELL's revenue grew at CAGRs of 16.5% and 7.4%, respectively. Its total assets grew at a CAGR of 10.5% over the past three years.
WELL's total revenues for the fiscal first quarter that ended March 31, 2024, amounted to $1.86 billion, up 19.2% year-over-year. Its adjusted EBITDA came to $732.37 million. The company's normalized FFO attributable to common stockholders stood at $585.21 million and $1.01 per share, up 39.5% and 18.8% from the prior-year quarter, respectively.
For the quarter ending June 30, 2024, WELL's revenue and <a href="https://www.investopedia.com/terms/f/fundsfromoperation.asp">FFO</a> are expected to increase 15.2% and 11.5% year-over-year to $1.92 billion and $1, respectively. It surpassed consensus FFO estimates in each of the trailing four quarters, which is impressive. The stock has gained 28% over the past year to close the last trading session at $103.35.
It's no surprise that WELL has a B grade for Growth, as reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.
Within the <a href="https://stocknews.com/category/reits-healthcare/">REITs - Healthcare</a> industry, it is ranked #9 out of 14 stocks. <a href="https://stocknews.com/stock/WELL/">Click here</a> for the additional POWR Ratings of WELL (Value, Momentum, Stability, Sentiment, and Quality).
Stock #2: CareTrust REIT, Inc. (<a href="https://stocknews.com/stock/CTRE/">CTRE</a>)
CTRE acquires, finances, develops, and owns real property for lease to third-party tenants in the healthcare sector. 
On June 4, 2024, CTRE celebrated its 10-year anniversary by announcing two strategic transactions totaling approximately $180 million, further proving its commitment to growth and excellence in the healthcare sector. They also quoted a reloaded pipeline of approximately $460 million.
On June 3, 2024, CTRE announced that it funded $90 million of a senior mortgage loan in connection with the borrower's acquisition of an 8-facility skilled nursing portfolio located in the Southeastern United States. The portfolio, consisting of 1,011 skilled nursing beds and 150 assisted living beds, had been acquired by an experienced regional healthcare real estate owner and operator.
CTRE has been paying dividends to its shareholders for the past nine years. Its annualized dividend of $1.16 per share translates to a dividend yield of 4.65% on the current share price. Its four-year average yield is 7.50%. Over the past five years, CTRE's dividend payments have grown at a CAGR of 5.8%.
Over the past three and five years, CTRE's revenue grew at CAGRs of 8.6% and 7.8%, respectively. Its EBIT grew at a CAGR of 11.1% over the past three years.
For the first quarter that ended March 31, 2024, the company's total revenues and normalized EBITDA attributable to CTRE stood at $63.07 million and $56.86 million, up 24.6% and 24.2% year-over-year, respectively. Its normalized FFO attributable to CTRE increased 32.9% from the year-ago quarter to $46.51 million. For the same quarter, its normalized FFO per share attributable to CTRE came in at $0.35.
Street expects CTRE's FFO and revenue for the quarter ending June 30, 2024, to increase 4.5% and 22.1% year-over-year to $0.37 and $62.93 million, respectively. The company surpassed consensus revenue estimates in each of the trailing four quarters. The stock has gained 25.7% over the past year to close the last trading session at $24.93.
CTRE has a B grade for Growth. It is ranked #7 in the same industry. Get CTRE's Value, Momentum, Stability, Sentiment, and Quality ratings <a href="https://stocknews.com/stock/CTRE/">here</a>.
Stock #1: Sabra Health Care REIT, Inc. (<a href="https://stocknews.com/stock/SBRA/">SBRA</a>)
SBRA's investment portfolio includes 377 real estate properties held for investment, 12 investments in loans receivable, five preferred equity investments, and two investments in unconsolidated joint ventures.
SBRA has been paying dividends to its shareholders for the past 12 years. Its annualized dividend of $1.20 per share translates to a dividend yield of 7.94% on the current share price. Its four-year average yield is 8.79%.
Over the past three and five years, SBRA's revenue grew at CAGRs of 2.7% and 2.1%, respectively.
SBRA's total revenues for the fiscal first quarter that ended March 31, 2024, increased 3.4% year-over-year to $166.75 million. Its cash, cash equivalents, and restricted cash at the end of the period rose 70.4% from the prior-year quarter to $65.93 million. In addition, its normalized FFO stood at $78.44 million, up 2% from the year-ago quarter. Also, its normalized FFO per common share grew 3% year-over-year to $0.34.
Analysts expect SBRA's revenue for the quarter ending June 30, 2024, to increase 2.7% year-over-year to $165.47 million. Its FFO for the quarter ending September 30, 2024, is expected to rise 4.2% year-over-year to $0.34. The company surpassed Street revenue estimates in three of the trailing four quarters. Over the past year, the stock has gained 25.1%, closing the last trading session at $15.12.
SBRA has a B grade for Growth. It is ranked #4 in the REITs - Healthcare industry. <a href="https://stocknews.com/stock/SBRA/">Click here</a> to see SBRA's Value, Momentum, Stability, Sentiment, and Quality ratings.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
WELL shares were trading at $103.66 per share on Friday afternoon, up $0.31 (+0.30%). Year-to-date, WELL has gained 16.43%, versus a 15.40% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Neha Panjwani</h2> <img src='https:/wp-content/uploads/2024/01/Neha-Panjwani_Headshot-1.jpeg' style="float:left; padding:5px;width:125px;">From her school days, Neha harbored a profound fascination for finance, a passion that steered her toward a career as an investment analyst following the completion of her bachelor's degree in commerce. Currently enrolled in the CFA program, Neha is dedicated to further enriching her comprehension of investment fundamentals.

Neha's primary objective is to aid retail investors in discerning optimal investment opportunities by diligently evaluating crucial aspects of financial instruments, with a primary focus on stocks and ETFs. Her commitment lies in empowering individuals to make informed and strategic investment decisions in the dynamic world of finance.<a href="https://stocknews.com/authors/?author=neha-panjwani">More...</a>The post <a href=https://stocknews.com/news/well-ctre-sbra-3-high-growth-healthcare-reits-to-watch/>3 High-Growth Healthcare REITs to Watch</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 High-Growth Healthcare REITs to Watch

Deutsche Bank's Fresh Money list for 3Q

REITs continue to reduce NAV discount amid increased rate cut hopes

Sabra Healthcare REIT (SBRA – Research Report), the Real Estate sector company, was revisited by a Wall Street analyst yesterday. Analyst Omotayo O...

Optimistic Outlook for Sabra Healthcare REIT: Strategic Acquisitions and Strong Performance Fuel Buy Rating


Daniel GoldmanHouse (D-NY)	$1K - $15K	stock	Sale	May 19, 2023	Apr 10, 2023	House
Daniel GoldmanHouse (D-NY)	$1K - $15K	stock	Purchase	Apr 17, 2023	Mar 01, 2023	House
Chris JacobsHouse (R-NY)	$1K - $15K	stock	Sale	Dec 12, 2022	Nov 08, 2022	House
Chris JacobsHouse (R-NY)	$15K - $50K	stock	Purchase	Jul 28, 2022	Jun 21, 2022	House

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Government Trades

Sabra Health Care REIT Inc

top performing SBRA trades